Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay
© Bozdagi et al.; licensee BioMed Central Ltd. 2013
Received: 2 January 2013
Accepted: 16 April 2013
Published: 27 April 2013
Haploinsufficiency of SHANK3, due to either hemizygous gene deletion (termed 22q13 deletion syndrome or Phelan-McDermid syndrome) or to gene mutation, accounts for about 0.5% of the cases of autism spectrum disorder (ASD) and/or developmental delay, and there is evidence for a wider role for SHANK3 and glutamate signaling abnormalities in ASD and related conditions. Therapeutic approaches that reverse deficits in SHANK3-haploinsufficiency may therefore be broadly beneficial in ASD and in developmental delay.
We observed that daily intraperitoneal injections of human insulin-like growth factor 1 (IGF-1) over a 2-week period reversed deficits in hippocampal α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) signaling, long-term potentiation (LTP), and motor performance that we had previously reported in Shank3-deficient mice. Positive effects were observed with an IGF-1 peptide derivative as well.
We observed significant beneficial effects of IGF-1 in a mouse model of ASD and of developmental delay. Studies in mouse and human neuronal models of Rett syndrome also show benefits with IGF-1, raising the possibility that this compound may have benefits broadly in ASD and related conditions, even with differing molecular etiology. Given the extensive safety data for IGF-1 in children with short stature due to primary IGF-1 deficiency, IGF-1 is an attractive candidate for controlled clinical trials in SHANK3-deficiency and in ASD.
KeywordsPharmacotherapy Personalized medicine Individualized medicine 22q13 deletion syndrome Phelan-McDermid syndrome
SHANK proteins are master scaffolding proteins of the postsynaptic density (PSD) of glutamatergic synapses and are critical determinants of glutamate transmission and synaptic spine dynamics . Loss of one functional copy of SHANK3 accounts for about 0.5% of the cases of autism spectrum disorder (ASD) and/or developmental delay , and there is likely a wider role for SHANK3 and glutamate signaling abnormalities in ASD and related neurodevelopmental disorders [3, 4]. Targeted disruption of the full-length form of Shank3 (sometimes called Shank3a) in mice leads to deficits in hippocampal AMPA signaling, long-term potentiation (LTP), and motor performance [5–7], likely reflecting delayed synaptic development as shown by the reduced AMPA signaling  and decreased levels of PSD-95 (unpublished results). IGF-1, which enters the central nervous system (CNS) through an interaction with lipoprotein-related receptor 1 (LRP1) , has multiple effects on neuronal and synaptic development and function, including effects on neurogenesis and synaptogenesis . IGF-1 treatment also enhances the PSD as measured both by PSD length and by levels of PSD-95 [10, 11]. Recombinant human IGF-1 has substantial human safety data and is approved for use in children, making IGF-1 an attractive compound for evaluation in neurodevelopmental disorders.
We first tested an active peptide derivative of IGF-1, (1–3)IGF-1, which has been shown to cross the blood–brain barrier and rescue Rett syndrome symptoms in Mecp2-deficient mice . We observed that intraperitoneal injections at 10 μg/g/day for 2 weeks restored normal hippocampal LTP in Shank3 heterozygous mice but had no effect on wild-type mice (repeated measures ANOVA was used to analyze the last five time points, F(3,11) = 6.07, P = 0.011). In post hoc analyses, vehicle-treated heterozygous mice were significantly different from wild-type mice (P = 0.004), while (1–3)IGF-1 treated heterozygous mice were not (P = 0.66). Furthermore, peptide treatment reversed deficits in the mean slope of the input/output (I/O) function (Figure 1b) (one-way ANOVA, F(3,19) = 4.25, P = 0.02). Vehicle-treated heterozygous mice were significantly different from vehicle-treated wild-type mice (P = 0.001), while (1–3)IGF-1 treated heterozygous mice were not different from vehicle-treated wild-type (P = 0.89), and there were no significant differences between vehicle-treated wild-type mice and wild-type mice treated with IGF-1 (P = 0.812), so further studies used just three conditions.
We next administered full-length IGF-1, like that used in children with short stature due to primary IGF-1 deficiency, by intraperitoneal injection at 240 μg/kg/day, starting at PND 13 to 15 and continuing for 2 weeks (Figure 2a). This dose, chosen because it represents the maximum dose according to the current FDA label for IGF-1, was effective in rescuing deficits in LTP (repeated measures ANOVA was used to analyze the last five time points, comparing heterozygous mice with and without IGF-1, F(1,6)=28.04, P=0.002). In contrast, lower dose IGF-1 (120 μg/kg/day for 2 weeks) was associated with more modest reversal of deficits in LTP (for the last five time points: F(1,6)=2.62, P=0.012), showing a dose–response effect and providing preclinical dosing information.
Specific deficits in the glutamate AMPA receptor component of neural signaling  were also reversed by a 2-week treatment of 240 μg/kg/day full-length IGF-1 (Figure 2b). The mean slope of the I/O function was 0.50 ± 0.14 for wild-type, 0.34 ± 0.06 for Shank3 heterozygotes and 0.61 ± 0.059 for IGF-1 injected heterozygotes (one-way ANOVA, F(2,9) = 8.62, P = 0.008). In post hoc analyses, vehicle-treated heterozygous mice were significantly different from vehicle-treated wild-type mice (P = 0.039), while IGF-1-treated heterozygous mice were not different from vehicle-treated wild-type mice (P = 0.12).
Patients with SHANK3-haploinsufficiency frequently present with hypotonia and motor deficits of variable severity, and we have observed subtle motor deficits in Shank3-heterozygous mice [5, 7]. After treating male heterozygous mice with 240 μg/kg/day for 2 weeks, we observed enhanced motor performance following treatment (Figure 2c) (F(2,20) = 3.98, P = 0.03).
Our results provide preclinical evidence for a beneficial role for IGF-1 in SHANK3-haploinsufficiency. Moreover, as there is emerging evidence that the SHANK3 pathway and the postsynaptic density, which it helps sculpt, play a role in many neurodevelopmental disorders, as evidenced by large-scale genetic, proteomic, and gene expression studies [3, 4, 14], therapies for SHANK3 deficiency and synaptic development represent important targets that could have a widespread positive impact for neurodevelopmental disorders. The beneficial effects of IGF-1 in models of Rett syndrome [11, 15] are consistent with this hypothesis.
There are some limitations to the current study. We, and others working with similar Shank3-deficient mice, see only limited behavioral abnormalities, with none except for rotarod deficits at the ages where we carried out the IGF-1 treatments and electrophysiological studies. For this reason, the phenotypes we measure are somewhat limited. In addition, a mechanistic understanding of the neuronal effects of IGF-1 has eluded the neuroscience community and we cannot precisely explain how IGF-1 reverses the deficits observed. We do hope, however, that our findings, together with those on IGF-1 in Rett syndrome models, may help spur further research on the action of IGF-1 in the CNS. We did not see any effect produced by the (1–3)IGF-1 peptide on control animals but we did not test the effects of full-length IGF-1 on wild-type mice. There could be enhanced LTP or rotarod performance in control animals following treatment with full-length IGF-1. Many drugs have effects on both healthy and non-healthy individuals and there is hence no a priori reason to assume that IGF-1 has no effect on control animals. In fact, given the positive effects of IGF-1 in Rett syndrome models it is likely that IGF-1 has a general effect on CNS function, which might also be observed in controls.
In summary, our results show that IGF-1, approved for use in children, can lead to functional improvements in a mouse model of ASD and developmental delay, representing an important preclinical step towards novel therapeutics. Clinical trials of IGF-1 in SHANK3-deficient individuals and in ASD are now underway (ClinicalTrials.gov Identifier NCT01525901).
Ankyrin repeat domain
Autism spectrum disorder
Central nervous system
Excitatory postsynaptic potential
Insulin-like growth factor 1
Lipoprotein-related receptor 1
Recombinant human IGF-1
This work was supported by the Seaver Foundation, the Simons Foundation, the NIMH (grant R01MH093725 to JDB), and by a gift from William Gibson and Paulina Rychenkova, PhD. We thank Catalina Betancur for helpful comments. Aspects of this work were presented at annual meetings of The Society for Neuroscience (2010, 2011) and the American Society of Human Genetics (2010), and at Phelan-McDermid Syndrome symposia (2011, 2012).
- Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED: ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem. 2002, 81 (5): 903-910. 10.1046/j.1471-4159.2002.00931.x.View ArticlePubMed
- Abrahams BS, Geschwind DH: Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008, 9 (5): 341-355. 10.1038/nrg2346.PubMed CentralView ArticlePubMed
- Sakai Y, Shaw CA, Dawson BC, Dugas DV, Al-Mohtaseb Z, Hill DE: Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med. 2011, 3 (86): 86ra49-10.1126/scitranslmed.3002166.PubMed CentralView ArticlePubMed
- Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE: FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011, 146 (2): 247-261. 10.1016/j.cell.2011.06.013.PubMed CentralView ArticlePubMed
- Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N: Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Aut. 2010, 1 (1): 15-10.1186/2040-2392-1-15.View Article
- Wang X, McCoy PA, Rodriguiz RM, Pan Y, Je HS, Roberts AC: Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 2011, 20 (15): 3093-3108. 10.1093/hmg/ddr212.PubMed CentralView ArticlePubMed
- Yang M, Bozdagi O, Scattoni ML, Wohr M, Roullet FI, Katz AM: Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci. 2012, 32 (19): 6525-6541. 10.1523/JNEUROSCI.6107-11.2012.PubMed CentralView ArticlePubMed
- Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez-Pinedo U: Neuronal activity drives localized blood–brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron. 2010, 67 (5): 834-846. 10.1016/j.neuron.2010.08.007.View ArticlePubMed
- O’Kusky JR, Ye P, D’Ercole AJ: Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci. 2000, 20 (22): 8435-8442.PubMed
- Shi L, Linville MC, Tucker EW, Sonntag WE, Brunso-Bechtold JK: Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb Cortex. 2005, 15 (5): 571-577.View ArticlePubMed
- Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD: Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009, 106 (6): 2029-2034. 10.1073/pnas.0812394106.PubMed CentralView ArticlePubMed
- Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007, 81 (6): 1289-1297. 10.1086/522590.PubMed CentralView ArticlePubMed
- Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K: Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet. 2011, 88 (3): 306-316. 10.1016/j.ajhg.2011.02.001.PubMed CentralView ArticlePubMed
- Laumonnier F, Cuthbert PC, Grant SG: The role of neuronal complexes in human X-linked brain diseases. Am J Hum Genet. 2007, 80 (2): 205-220. 10.1086/511441.PubMed CentralView ArticlePubMed
- Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y: A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010, 143 (4): 527-539. 10.1016/j.cell.2010.10.016.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.